Intelligence Feed event · Policy · 2026-08-27

    FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer

    Question

    FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer

    Direct answer

    Revolution Medicines achieved FDA approval for RASONQUE (daraxonrasib), establishing the first broad RAS-targeted therapeutic on the market for metastatic pancreatic adenocarcinoma. The regulatory decision follows data from the Phase 3 RASolute 302 study. The approved indication addresses patients with prior systemic treatment or those unable to tolerate intensive multiagent chemotherapy regimens. Commercial distribution will be facilitated in part via Onco360's national specialty pharmacy network.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-27
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer”, revision 1, evidence through 2026-08-27. https://marketontology.com/market-events/2026-08-27/fda-approves-revolution-medicines-rasonque-in-pancreatic-cancer-d6bed3

    POLICY
    FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer
    Revolution Medicines achieved FDA approval for RASONQUE (daraxonrasib), establishing the first broad RAS-targeted therapeutic on the market for metastatic pancreatic adenocarcinoma. The regulatory decision follows data from the Phase 3 RASolute 302 study. The approved indication addresses patients with prior systemic treatment or those unable to tolerate intensive multiagent chemotherapy regimens. Commercial distribution will be facilitated in part via Onco360's national specialty pharmacy network.
    RVMD
    Impact
    73
    AUG 27
    SIG
    92%
    RVMD
    FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer
    Revolution Medicines achieved FDA approval for RASONQUE (daraxonrasib), establishing the first broad RAS-targeted therapeutic on the market for metastatic pancreatic adenocarcinoma. The regulatory decision follows data from the Phase 3 RASolute 302 study. The approved indication addresses patients with prior systemic treatment or those unable to tolerate intensive multiagent chemotherapy regimens. Commercial distribution will be facilitated in part via Onco360's national specialty pharmacy network.
    → First-in-class oncology approval unlocks commercial product revenue for RVMD while driving specialized dispensing volume for distribution partner Onco360.
    Impact
    Revolution Medicines achieved FDA approval for RASONQUE (daraxonrasib), establishing the first broad RAS-targeted therapeutic on the market for metastatic pancreatic adenocarcinoma. The regulatory decision follows data from the Phase 3 RASolute 302 study. The approved indication addresses patients with prior systemic treatment or those unable to tolerate intensive multiagent chemotherapy regimens. Commercial distribution will be facilitated in part via Onco360's national specialty pharmacy network.
    Affected
    RVMD
    Transmission
    First-in-class oncology approval unlocks commercial product revenue for RVMD while driving specialized dispensing volume for distribution partner Onco360.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDcommercial drug launch revenue recognitionUp1-3mFDA approval granted for RASONQUE (daraxonrasib) in metastatic pancreatic cancer

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month